Prelude Therapeutics Incorporated (PRLD) Dividend History

Company News

• Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

  Prelude Therapeutics announced positive initial clinical data for its SMARCA2 degrader PRT3789 in a Phase 1 trial, showing promising anti-tumor activity and a generally well-tolerated safety profile in patients with SMARCA4-mutated cancers.

  GlobeNewswire Inc.
• Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

  WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

  GlobeNewswire Inc.
• Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

  WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14.

  GlobeNewswire Inc.
• Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

  First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024

  GlobeNewswire Inc.
• Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

  Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses

  GlobeNewswire Inc.